Dose Escalation Study to Evaluate the Safety and Antiviral Activity of Val-mCyd in Adults With Chronic Hepatitis C

Completed · Phase 1/Phase 2

Conditions studied: Chronic Hepatitis C

In brief

This study was conducted to determine the safety, tolerance, pharmacokinetics and antiviral activity of val-mCyd at doses ranging from 50 mg to 800 mg per day.

Key facts

Study ID

NCT00227435

Run by

Merck Sharp & Dohme LLC

Starts

2003-02-01

Expected to finish

2004-07-01

Last updated by the study team

2016-04-27

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Documented clinical history of chronic hepatitis C and compensated liver disease
• No antiviral treatment for hepatitis C in the 6 months prior to the Screening visit
• Other protocol-defined inclusion criteria may apply.

You may not qualify if…

• Patient is pregnant or breastfeeding
• Patient is co-infected with HBV or HIV
• Other protocol-defined exclusion criteria may apply.

Where it is running

• Study site — Pasadena, California, United States
• Study site — Boston, Massachusetts, United States
• Study site — Worcester, Massachusetts, United States
• Study site — Fairfax, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.